“…Besides the critical role of IMP3 in fetal development ( Mueller-Pillasch et al, 1999 ) and fertility ( Li et al, 2014 ; Hammer et al, 2005 ), its importance as an oncogene in several kinds of cancer was determined in the last few years: Expression of IMP3 could be observed in colon carcinoma ( Li et al, 2009 ; Lochhead et al, 2012 ; Kumara et al, 2015 ), adenocarcinomas ( Bellezza et al, 2009 ; Lu et al, 2009 ; Gao et al, 2014 ), urothelial carcinomas ( Sitnikova et al, 2008 ; Xylinas et al, 2014 ), lymphomas ( King et al, 2009 ; Tang et al, 2013 ; Hartmann et al, 2012 ), renal cell carcinomas ( Hoffmann et al, 2008 ; Jiang et al, 2006 ; 2008 ), and many more ( Hammer et al, 2005 ; Chen et al, 2013 ; Walter et al, 2009 ; Köbel et al, 2009 ; Zhou et al, 2014 ). Additionally, high expression of IMP3 often correlates with poor survival prognosis for patients ( Hoffmann et al, 2008 ; Jiang et al, 2006 ; Köbel et al, 2009 ; Yuan et al, 2009 ; Lin et al, 2013 ).…”